Alaunos Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Alaunos Therapeutics sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Alaunos Therapeutics: 22 sponsored US clinical trials, none currently recruiting.
Alaunos Therapeutics sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 1 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Cancer, with 2 trials.
Top-decile sponsor footprint
Alaunos Therapeutics ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
22 total, page 1 of 1
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
NCT05292859
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
NCT05194735
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
NCT05124743
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
NCT04006119
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
NCT03679754
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
NCT03636477
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
NCT03330197
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
NCT02423902
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
NCT02026271
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
NCT01703754
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
NCT01397708
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
NCT01168791
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
NCT01139346
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
NCT00815607
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
NCT00608803
Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans
NCT00591890
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
NCT00421213
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
NCT00421135
Study of ZIO-201 in Advanced Sarcoma
NCT00439686
Study of ZIO-101 in Multiple Myeloma
NCT00303199
A Phase I Trial of ZIO-101 in Solid Tumors
NCT00591396
A Phase I Trial of ZIO-101 in Hematologic Cancers
NCT00592046
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Therapeutic Areas
How the Alaunos Therapeutics early-phase archive is shaped
22 indexed studies, none listed as recruiting (0% open); 16 completed (73%).
Phase mix: 1 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Advanced Cancer (2 trials), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Alaunos Therapeutics: archived-pipeline peers nationwide
Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Alaunos Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 archived trials
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
- Griffin Hospital · 22 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Alaunos Therapeutics page
22 registered trials is a research-attention snapshot, not an endorsement of Alaunos Therapeutics or any single study.
- None of Alaunos Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Advanced Cancer is the condition Alaunos Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alaunos Therapeutics pipeline card: 22 registered trials from official public datasets.Report a data error.